| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/100-1/200 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ABRAXAS2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于ABRAXAS2抗体的示例参考文献(注：内容为示例性概括，实际文献可能需要根据具体研究补充)：
1. **文献名称**: "ABRAXAS2 modulates DNA repair by regulating BRCA1 localization"
**作者**: Smith J, et al.
**摘要**: 研究通过开发特异性ABRAXAS2抗体，揭示了其在DNA损伤应答中调控BRCA1复合体核定位的机制，提示其与卵巢癌易感性相关。
2. **文献名称**: "A novel antibody-based assay for detecting ABRAXAS2 in Fanconi anemia pathway"
**作者**: Lee H, et al.
**摘要**: 报道了一种高灵敏度单克隆抗体的制备，用于检测ABRAXAS2在范可尼贫血通路中的表达水平，证实其与FANCD2蛋白存在功能协同。
3. **文献名称**: "ABRAXAS2 interacts with PALB2 to maintain genomic stability"
**作者**: Garcia M, et al.
**摘要**: 利用免疫共沉淀(Co-IP)结合ABRAXAS2抗体，发现其与PALB2的相互作用对同源重组修复至关重要，缺失导致细胞对PARP抑制剂敏感。
4. **文献名称**: "Prognostic significance of ABRAXAS2 in breast cancer"
**作者**: Wang Y, et al.
**摘要**: 通过免疫组化分析ABRAXAS2表达，发现其低表达与乳腺癌患者不良预后相关，提示其作为潜在生物标志物的价值。
(注：以上为假设性示例，实际文献需通过PubMed/Google Scholar检索确认)
The ABRAXAS2 (also known as BRCC3/BRCA1-A complex subunit 2) antibody is a tool used to study the role of ABRAXAS2. a key component of the BRCA1-A macromolecular complex involved in DNA damage response and repair. ABRAXAS2 interacts with BRCA1. BRCC36. and other proteins to form a deubiquitinating enzyme complex critical for homologous recombination repair (HRR) of DNA double-strand breaks. This pathway is essential for maintaining genomic stability, and its dysfunction is linked to cancer susceptibility, particularly in BRCA1/2-mutated tumors.
ABRAXAS2 antibodies are widely employed in research to investigate protein-protein interactions, subcellular localization, and expression levels in cellular models or tumor tissues. They are used in techniques like Western blotting, immunoprecipitation, and immunofluorescence. Studies have highlighted ABRAXAS2's role in regulating HRR efficiency, cell cycle checkpoints, and resistance to PARP inhibitors, making it a potential biomarker or therapeutic target in cancers with defective DNA repair mechanisms (e.g., breast, ovarian, or prostate cancers). Additionally, ABRAXAS2 expression patterns may help stratify patients for targeted therapies, such as PARP inhibitors, which exploit synthetic lethality in HRR-deficient cells. The antibody's specificity and validation in experimental models remain critical for elucidating ABRAXAS2's functional contributions to genomic integrity and cancer progression.
×
